Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer

References

• Angelova M, Charoentong P, Hackl H, Trajanoski Z. The colorectal cancer immune paradox revisited. Oncoimmunology. 2016;5(2):e1078058. doi:10.1080/2162402X.2015.1078058.
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–8. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ge X, He J, Cheng Y, Wang Z, Wang J, Sun L. The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis. World J Surg Oncol. 2019;17(1):85. doi:10.1186/s12957-019-1621-9.
   PubMed Web of Science ®Google Scholar
• Eriksen AC, Sorensen FB, Lindebjerg J, Hager H, dePont Christensen R, Kjær-Frifeldt S, Hansen TF. The prognostic value of tumor-infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study. Transl Oncol. 2018;11(4):979–987. doi:10.1016/j.tranon.2018.03.008.
   PubMed Web of Science ®Google Scholar
• Giannakis M, Mu XJ, Shukla SA, Qian Z, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15(4):857–865. doi:10.1016/j.celrep.2016.03.075.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Ou F-S, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 2019;37(14):1217–1227. doi:10.1200/JCO.18.01798.
   PubMed Web of Science ®Google Scholar
• Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008;134(4):988–997. doi:10.1053/j.gastro.2008.01.015.
   PubMed Web of Science ®Google Scholar
• Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, Laurent M, Berthet P, Mauillon J,  Fiore F,  Sabourin J-C, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009;22(9):1186–1195. doi:10.1038/modpathol.2009.80.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G,  Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–3226. doi:10.1200/JCO.2009.27.1825.
   PubMed Web of Science ®Google Scholar
• Shia J, Ellis NA, Paty PB,  Nash GM, Qin J, Offit K,  Zhang X-M,  Markowitz AJ, Nafa K,  Guillem JG, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003;27(11):1407–1417.
   PubMed Web of Science ®Google Scholar
• Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L, Li C. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(6):1595–1605. doi:10.1038/bjc.2014.46.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8(327):327ra26. doi:10.1126/scitranslmed.aad6352.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum, version 3.4.0.0. www.cap.org
   Google Scholar
• Ko SY, Pyo J-S. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Int J Biol Markers 2019;34(2):132–138.
   Google Scholar
• Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola F, Bedognetti D, Hendrickx W. Immunogenomic classification of colorectal cancer and therapeutic implications. Int J Mol Sci. 2017;18(10):2229. doi:10.3390/ijms18102229.
   PubMed Web of Science ®Google Scholar
• Kong JC, Guerra GR, Pham T, Mitchell C, Lynch AC, Warrier SK, Ramsay RG, Heriot AG. Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2019;62(4):498–508. doi:10.1097/DCR.0000000000001332.
   PubMed Web of Science ®Google Scholar
• Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, et al. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019;121(8):659–665. doi:10.1038/s41416-019-0559-6.
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang S-J, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179. doi:10.1038/srep15179.
   PubMed Web of Science ®Google Scholar
• College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum, version 4.0.1.0. www.cap.org
   Google Scholar
• Konishi T, Shimada Y, Lee LH, Cavalcanti MS, Hsu M, Smith JJ, Nash GM, Temple LK, Guillem JG, Paty PB, et al. Poorly differentiated clusters predict colon cancer recurrence: an in-depth comparative analysis of invasive-front prognostic markers. Am J Surg Pathol. 2018;42(6):705–714. doi:10.1097/PAS.0000000000001059.
   PubMed Web of Science ®Google Scholar
• Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA,  Fang CG, Palmieri M,  Parsons MJ, et al. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut. 2018. doi:10.1136/gutjnl-2017-315664.
   Web of Science ®Google Scholar
• Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–5951. doi:10.1200/JCO.2008.19.6147.
   PubMed Web of Science ®Google Scholar
• Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SAA, Bassett R, Castillo M, et al. Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the international TILs working group. Ann Surg Oncol. 2016;23(7):2242–2248. doi:10.1245/s10434-016-5173-8.
   PubMed Web of Science ®Google Scholar
• van Putten PG, van Lier MG, Hage M, Biermann K, van Rijssel RH, Westenend PJ, Morreau H, Steyerberg EW, Dinjens WNM, Kuipers EJ, et al. Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. Fam Cancer. 2014;13(3):351–359. doi:10.1007/s10689-014-9705-8.
   PubMed Web of Science ®Google Scholar
• Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39(1):116–125. doi:10.1016/j.humpath.2007.05.022.
   PubMed Web of Science ®Google Scholar
• Amin MB, Gress DM, Vega M, et al. AJCC cancer staging manual, 8th ed. NewYork, NY: Springer;2016.
   Google Scholar
• American Society of Clinical Oncology. Guidelines for gastrointestinal cancer. https://www.asco.org/research-guidelines/quality-guidelines/guidelines/gastrointestinal-cancer.
   Google Scholar
• National Comprehensive Cancer Network. Guidelines for colon and rectal cancer. https://www.nccn.org/professionals/physician_gls/default.aspx#site.
   Google Scholar
• Williams BA, Mandrekar JN, Mandrekar SS. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Mayo Clinic: Rochester (Minn.). www.mayo.edu/research/documents/biostat-79pdf/doc-10027230
   Google Scholar
• Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92(4):965–970. doi:10.1093/biomet/92.4.965.
   Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346. doi:10.1016/0197-2456(96)00075-X.
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Wirta E-V, Seppala T, Friman M, Väyrynen J, Ahtiainen M, Kautiainen H, Kuopio T, Kellokumpu I, Mecklin J-P, Böhm J, et al. Immunoscore in mismatch repair-proficient and -deficient colon cancer. J Pathol Clin Res. 2017;3(3):203–213. doi:10.1002/cjp2.71.
   PubMedGoogle Scholar
• Ogino S, Giannakis M. Immunoscore for (colorectal) cancer precision medicine. Lancet. 2018;391(10135):2084–2086. doi:10.1016/S0140-6736(18)30953-X.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Catherine C Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31(7):921–929. doi:10.1016/j.annonc.2020.03.310.
   PubMed Web of Science ®Google Scholar
• Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10(4):293–300. doi:10.2353/jmoldx.2008.080031.
   PubMed Web of Science ®Google Scholar
• Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91(12):2417–2422. doi:10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U.
   PubMed Web of Science ®Google Scholar
• Turksma AW, Coupe VM, Shamier MC, Lam KLH, de Weger VA, Belien JAM, van den Eertwegh AJ, Meijer GA, Meijer CJLM, Hooijberg E, et al. Extent and location of tumor-infiltrating lymphocytes in microsatellite-stable colon cancer predict outcome to adjuvant active specific immunotherapy. Clin Cancer Res. 2016;22(2):346–356. doi:10.1158/1078-0432.CCR-13-2462.
   PubMed Web of Science ®Google Scholar